[Does intracoronary abciximab improve the outcome of percutaneous coronary interventions? A randomized controlled trial].

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Revista Española de Cardiología

• Publication date

  2006-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1885-5857(07)60020-6PMID 16790200
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Guías de Práctica Clínica sobre intervencionismo coronario percutáneo

  2005cited by this paper
• Instant dissolution of intracoronary thrombus by abciximab.

  2005cited by this paper
• Documento de Consenso de Expertos sobre el uso de agentes antiplaquetarios

  2004cited by this paper
• Daño miocárdico por reperfusión

  2004cited by this paper
• Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS.

  2004cited by this paper
• Efficacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions: a meta-analysis of randomized, controlled trials.

  2004cited by this paper
• [Expert consensus document on the use of antiplatelet agents].

  2004cited by this paper
• Comparison of intracoronary vs. intravenous administration of abciximab in coronary stenting

  2004cited by this paper
• Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention

  2004cited by this paper
• Reduction of Major Adverse Cardiac Events With Intracoronary Compared With Intravenous Bolus Application of Abciximab in Patients With Acute Myocardial Infarction or Unstable Angina Undergoing Coronary Angioplasty

  2003cited by this paper
• [Present and future of antithrombotic therapy in acute coronary syndromes].

  2003cited by this paper
• Presente y futuro del tratamiento antitrombótico en el síndrome coronario agudo

  2003cited by this paper
• Influencia de la diabetes mellitus en los resultados clínicos tras revascularización coronaria percutánea

  2002cited by this paper
• [Influence of diabetes mellitus on clinical outcome after percutaneous coronary revascularization].

  2002cited by this paper
• Effectiveness of tirofiban, eptifibatide, and abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study).

  2002cited by this paper
• [Does abciximab improve the prognosis of diabetics after percutaneous coronary intervention?].

  2002cited by this paper
• [Quick resolution with abciximab of giant coronary thrombus].

  2002cited by this paper
• El abciximab mejora el pronóstico de los diabéticos tras la intervención coronaria percutánea

  2002cited by this paper
• Rápida lisis de gran trombo coronario con abciximab

  2002cited by this paper
• Effect of Abciximab on cardiac enzyme elevation after transluminal extraction atherectomy (TEC) in high‐risk saphenous vein graft lesions: Comparison with a historical control group

  2001cited by this paper
• Abciximab reduces mortality in diabetics following percutaneous coronary intervention.

  2000cited by this paper
• Is a strategy of intended incomplete percutaneous transluminal coronary angioplasty revascularization acceptable in nondiabetic patients who are candidates for coronary artery bypass graft surgery? The Bypass Angioplasty Revascularization Investigation (BARI).

  1999cited by this paper
• Usefulness of platelet glycoprotein IIb/IIIa inhibitors in coronary stenting for reconstruction of complex lesions: procedural and 30 day outcome.

  1999cited by this paper
• Minimal myocardial damage during coronary intervention is associated with impaired outcome.

  1999cited by this paper
• Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

  1998cited by this paper
• Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators.

  1998cited by this paper
• Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications.

  1998cited by this paper
• Abciximab

  1998cited by this paper
• Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.

  1997cited by this paper
• Long-term Protection From Myocardial Ischemic Events in a Randomized Trial of Brief Integrin β3 Blockade With Percutaneous Coronary Intervention

  1997cited by this paper
• Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Compl

  1997cited by this paper
• 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1.

  1997cited by this paper
• Abciximab: A New Antiaggregant Used in Angioplasty

  1996cited by this paper
• Prevention of cardiovascular ischemic complications with new platelet glycoprotein IIb/IIIa inhibitors.

  1995cited by this paper

• Intracoronary versus intravenous administration of abciximab during percutaneous coronary intervention for acute coronary syndrome : grading the evidence through a meta-analysis of randomized controlled trials

  2016influential citation
• Appropriate bolus administration of glycoprotein IIb/IIIa inhibitors for patients with acute coronary syndromes undergoing percutaneous coronary intervention: intracoronary or intravenous? A comprehensive and updated meta-analysis and systematic review.

  2015cites this paper
• Complications of intracoronary abciximab bolus-only versus standard protocol during percutaneous coronary intervention in acute coronary syndrome

  2014cites this paper
• Intracoronary abciximab reduces death and major adverse cardiovascular events in acute coronary syndromes: a meta-analysis of clinical trials.

  2013influential citation
• Intracoronary Reopro during Percutaneous Coronary Intervention in Acute and Stable Patient can Influence Stent Thrombosis Formation (IRPASST) Study

  2013cites this paper
• 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention

  2013cites this paper
• Intracoronary versus Intravenous Administration of Abciximab in Patients with Acute Coronary Syndrome: A Meta-Analysis

  2013cites this paper
• A comparison of intracoronary with intravenous glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention in patients with acute coronary syndrome: a meta-analysis of randomized controlled trials.

  2012cites this paper
• Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: A meta-analysis of randomized trials

  2012cites this paper
• 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary

  2012cites this paper
• Meta-analysis of prospective randomized controlled trials comparing intracoronary versus intravenous abciximab in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.

  2012cites this paper
• Updated evidence on intracoronary abciximab in ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials.

  2012cites this paper
• Intracoronary use of GP IIb/IIIa inhibitors in percutaneous coronary interventions.

  2012cites this paper
• Cardiovascular Angiography and Interventions Association Task Force on Practice Guidelines and the Society for Report of the American College of Cardiology Foundation/American Heart 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention : A

  2012cites this paper
• on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions the American College of Cardiology Foundation/American Heart Association Task Force 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention : A Report of

  2012cites this paper
• 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.

  2011cites this paper
• ACCF/AHA/SCAI Practice Guideline 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventi

  2011cites this paper
• Intracoronary compared to intravenous bolus abciximab during primary percutaneous coronary intervention in ST-segment Elevation Myocardial Infarction (STEMI) patients reduces 30-day mortality and target vessel revascularization: a randomized trial.

  2011cites this paper
• ACCF/AHA/SCAI Practice Guideline 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions

  2011cites this paper
• Strategia leczenia abciksimabem u pacjentów z ostrymi zespołami wieńcowymi. Analiza przesłanek teoretycznych i wyników badań klinicznych

  2011cites this paper
• the Society for Cardiovascular Angiography and Interventions Foundation/American Heart Association Task Force on Practice Guidelines and Executive Summary : A Report of the American College of Cardiology 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention:

  2011cites this paper
• Meta-analysis of randomized controlled trials of intracoronary versus intravenous administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention for acute coronary syndrome.

  2011cites this paper
• Intracoronary versus intravenous abciximab administration in STEMI patients: overview of current status and open questions

  2011cites this paper
• 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.

  2011cites this paper
• 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.

  2011cites this paper
• Improved clinical outcomes with intracoronary compared to intravenous abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a systematic review and meta-analysis.

  2010cites this paper
• Intracoronary compared to intravenous Abciximab and high-dose bolus compared to standard dose in patients with ST-segment elevation myocardial infarction undergoing transradial primary percutaneous coronary intervention: a two-by-two factorial placebo-controlled randomized study.

  2010cites this paper
• Estudio aleatorizado con abciximab o eptifibatide en angioplastia coronaria compleja. Resultados intrahospitalarios y a 30 dias

  2010cites this paper
• Intracoronary glycoprotein IIb/IIIa inhibitors from questioning the logic to weighing the data.

  2010cites this paper
• Same dose of drug, different magnitude of effect?

  2010cites this paper
• Reperfusión mecánica en el síndrome coronario agudo con elevación del segmento ST. Situación actual de la angioplastia primaria en España

  2009cites this paper
• Effects of intracoronary compared to intravenous abciximab administration in patients undergoing transradial percutaneous coronary intervention: A sub-analysis of the EASY trial.

  2009cites this paper
• Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention--effects on soluble CD40 ligand concentrations.

  2009cites this paper
• Intracoronary versus intravenous abciximab in ST-segment elevation myocardial infarction: rationale and design of the CICERO trial in patients undergoing primary percutaneous coronary intervention with thrombus aspiration

  2009cites this paper
• Drug Safety Evaluation

  2008cites this paper
• Intracoronary Compared With Intravenous Bolus Abciximab Application in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: The Randomized Leipzig Immediate Percutaneous Coronary Intervention Abciximab IV Versus IC in ST-Elevation Myocardial Infarct

  2008influential citation
• [Revista Espanola de Cardiologia 2007: scientific impact, manuscript management, activity, and diffusion].

  2007cites this paper
• Cardiología intervencionista 2006

  2007cites this paper
• [Interventional cardiology 2006].

  2007cites this paper